XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restructuring Charges (Notes)
 9 Months Ended
Sep. 30, 2017
Restructuring Charges [Abstract]  
Restructuring and Related Activities Disclosure [Text Block]
Restructuring Charges

During the nine months ended September 30, 2017, we incurred restructuring charges related to the acquisition of the HIS business (see Note 3: Acquisition, Strategic Transaction and Integration Expenses). The restructuring charges were incurred as a result of integrating the acquired operations into our business and include severance costs related to involuntary employee terminations and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer. We expect to complete these restructuring activities by the end of 2017. All material charges in regard to these restructuring activities have been incurred as of September 30, 2017.

During the year ended December 31, 2015, we incurred restructuring charges related to an agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement. The buy-out, including payroll taxes, is paid in equal monthly installments until December 2020.

The following table summarizes the details of changes in our restructuring-related accrual for the period ending September 30, 2017 (in thousands):

 
Accrued Balance December 31, 2016
 
Charges
Incurred
 
Payments
 
Other Adjustments
 
Accrued Balance
September 30,
 2017
Severance pay and benefits
$
53

 
$
14,600

 
$
(12,010
)
 
$
(17
)
 
$
2,626

Employment agreement buyout
1,477

 
—

 
(273
)
 
—

 
1,204

Facility closure expenses
—

 
4,410

 
(2,458
)
 
(1,952
)
 
—

 
$
1,530

 
$
19,010

 
$
(14,741
)
 
$
(1,969
)
 
$
3,830